Trial Profile
Phase 2 Trial of Intensive Chemo-immunotherapy With Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 15 Mar 2024 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 15 Mar 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
- 06 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.